You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

Investigational Drug Information for Sapanisertib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Sapanisertib?

Sapanisertib is an investigational drug.

There have been 24 clinical trials for Sapanisertib. The most recent clinical trial was a Phase 2 trial, which was initiated on August 12th 2015.

The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc., and M.D. Anderson Cancer Center.

There are ninety-six US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Sapanisertib
TitleSponsorPhase
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung CancerCalithera Biosciences, IncPhase 2
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME StudyNational Cancer Institute (NCI)Phase 1/Phase 2
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME StudyM.D. Anderson Cancer CenterPhase 1/Phase 2

See all Sapanisertib clinical trials

Clinical Trial Summary for Sapanisertib

Top disease conditions for Sapanisertib
Top clinical trial sponsors for Sapanisertib

See all Sapanisertib clinical trials

US Patents for Sapanisertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sapanisertib ⤷  Sign Up Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH) ⤷  Sign Up
Sapanisertib ⤷  Sign Up Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) ⤷  Sign Up
Sapanisertib ⤷  Sign Up Method of targeting glycoproteins to treat cancer Board of Regents of the University of Nebraska (Lincoln, NE) ⤷  Sign Up
Sapanisertib ⤷  Sign Up Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-- trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use Signal Pharmaceuticals, LLC (San Diego, CA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sapanisertib

Drugname Country Document Number Estimated Expiration Related US Patent
Sapanisertib Australia AU2014348657 2033-11-13 ⤷  Sign Up
Sapanisertib Australia AU2017245411 2033-11-13 ⤷  Sign Up
Sapanisertib Australia AU2019246853 2033-11-13 ⤷  Sign Up
Sapanisertib Brazil BR112016010716 2033-11-13 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.